You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Express Scripts
Dow
Moodys
McKesson

Last Updated: September 26, 2023

Investigational Drug Information for PSN-632,408


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug PSN-632,408?

PSN-632,408 is an investigational drug.

There have been 7 clinical trials for PSN-632,408. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2020.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Neurotoxicity Syndromes, and Leukemia. The leading clinical trial sponsors are Sanofi, National Cheng-Kung University Hospital, and University of Pisa.

There are sixty-one US patents protecting this investigational drug and five hundred and ninety-seven international patents.

Recent Clinical Trials for PSN-632,408
TitleSponsorPhase
Topical Vancomycin Over Sternal Edge in Cardiac SurgeryNational Cheng-Kung University HospitalPhase 4
Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot StudyUniversity of AlbertaN/A
Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot StudyUniversity of TorontoN/A

See all PSN-632,408 clinical trials

Clinical Trial Summary for PSN-632,408

Top disease conditions for PSN-632,408
Top clinical trial sponsors for PSN-632,408

See all PSN-632,408 clinical trials

US Patents for PSN-632,408

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PSN-632,408 ⤷  Try a Trial Generation of muscle lineage cells and therapeutic uses thereof GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) ⤷  Try a Trial
PSN-632,408 ⤷  Try a Trial Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent The University of Queensland (Queensland, AU) ⤷  Try a Trial
PSN-632,408 ⤷  Try a Trial Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals Sanofi-Aventis (Paris, FR) ⤷  Try a Trial
PSN-632,408 ⤷  Try a Trial Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use Sanofi-Aventis (Paris, FR) ⤷  Try a Trial
PSN-632,408 ⤷  Try a Trial Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level Arena Pharmaceuticals, Inc. (San Diego, CA) ⤷  Try a Trial
PSN-632,408 ⤷  Try a Trial Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level Arena Pharmaceuticals, Inc. (San Diego, CA) ⤷  Try a Trial
PSN-632,408 ⤷  Try a Trial GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto Arena Pharmaceuticals, Inc. (San Diego, CA) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PSN-632,408

Drugname Country Document Number Estimated Expiration Related US Patent
PSN-632,408 Australia AU2017351638 2036-10-26 ⤷  Try a Trial
PSN-632,408 Canada CA3044691 2036-10-26 ⤷  Try a Trial
PSN-632,408 China CN110730819 2036-10-26 ⤷  Try a Trial
PSN-632,408 European Patent Office EP3532605 2036-10-26 ⤷  Try a Trial
PSN-632,408 World Intellectual Property Organization (WIPO) WO2018076060 2036-10-26 ⤷  Try a Trial
PSN-632,408 Australia AU2015268101 2034-05-27 ⤷  Try a Trial
PSN-632,408 Australia AU2021202648 2034-05-27 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Express Scripts
Dow
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.